

Chinese biopharma



China is the global leader in **innovation**, **out-licensing**, and **regulatory integration**.



Out-licensing surged to **\$50 billion** in 2025, maintaining high growth rates.



66% of globally approved NASS secured marketing authorisation in China.



China is the **global leader** in targeted protein degradation research papers and patents.

Unprecedented growth

Since 2022, Chinese biopharma out-licensing surged, **reaching \$50 billion in 2025**, 8% of global deals. With **35% annual growth** and sought-after assets due to cost advantages and quality clinical data, China solidifies its global competitiveness, driving innovation and collaboration in the biopharma industry.




Projected to grow at **35%** annually


Government support

Comprehensive "end-to-end innovation support" policies, including fast-track clinical trial approvals and the integration of commercial health insurance, have accelerated the development and commercialisation of innovative drugs.

Projected annual growth (billion US \$)



Projected market share in 2025



TPD leadership

China leads in targeted protein degradation (TPD) technology, contributing 38% of global research papers, 37% of patents, and 30% of drug candidates by 2024.

This innovation addresses "undruggable" targets, earning global recognition and fostering biopharma collaboration.